Literature DB >> 8193407

Unusual coexistence of systemic lupus erythematosus and primary biliary cirrhosis.

F Nachbar1, H C Korting, R M Hoffmann, M Kollmann, M Meurer.   

Abstract

Systemic lupus erythematosus (SLE) and primary biliary cirrhosis (PBC) are distinct clinical disorders which rarely occur in the same patient. We report on a 65-year-old woman with coexistence of both conditions. Diagnosis of SLE was ascertained by the presence of seven ACR criteria (cutaneous lesions, photosensitivity, antinuclear and anti-double-stranded-DNA antibodies, pancytopenia, arthritis, oral lesions). PBC was disclosed by clinical investigation, liver histology and highly positive antimitochondrial M2 antibodies. The most important differential diagnoses of lupus hepatitis are PBC and autoimmune hepatitis. Diagnostic criteria for these conditions are discussed, and previous reports on overlap between SLE and PBC are reviewed.

Entities:  

Mesh:

Year:  1994        PMID: 8193407     DOI: 10.1159/000247174

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  Primary sclerosing cholangitis associated with lupus nephritis: a rare association.

Authors:  Yoshiko Kadokawa; Katsuhisa Omagari; Isao Matsuo; Yoshiko Otsu; Umpei Yamamoto; Tomoya Nishino; Kazuo Ohba; Masanobu Miyazaki; Takashi Harada; Takashi Taguchi; Shigeru Kohno
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

Review 2.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

3.  Involvement of the liver in rheumatic diseases.

Authors:  Hiromasa Ohira; Kazumichi Abe; Atsushi Takahashi
Journal:  Clin J Gastroenterol       Date:  2011-11-26

Review 4.  Clinical Characteristics of Concomitant Systemic Lupus Erythematosus and Primary Biliary Cirrhosis: A Literature Review.

Authors:  Toru Shizuma
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.